Plasmacytomas expressing immunoglobulin A are rare and not well characterized. In this study, 9 cases of IgA-positive plasmacytoma presenting in lymph node and 3 in extranodal sites were analyzed by morphology, immunohistochemistry, and polymerase chain reaction examination of immunoglobulin heavy and k light chain genes. Laboratory features were correlated with clinical findings. There were 7 males and 5 females; age range was 10 to 66 years (median, 32 y). Six of the patients were younger than 30 years of age, 5 of whom had nodal disease. About 67% (6 of 9) of the patients with nodal disease had evidence of immune system dysfunction, including human immunodeficiency virus infection, T-cell deficiency, autoantibodies, arthritis, Sjo¨gren syndrome, and decreased B cells. An IgA M-spike was detected in 6 of 11 cases, and the M-protein was nearly always less than 30 g/L. All patients had an indolent clinical course without progression to plasma cell myeloma. Histologically, nodal IgA plasmacytomas showed an interfollicular or diffuse pattern of plasma cell infiltration. The plasma cells were generally of mature Marschalko type with little or mild pleomorphism and exclusive expression of monotypic IgA. There was an equal expression of k and l light chains (ratio 6:6). Clonality was showed in 9 of 12 cases: by polymerase chain reaction in 7 cases, by cytogenetic analysis in 1 case, and by immunofixation in 1 case. Clonality did not correlate with pattern of lymph node infiltration. Our results suggest that IgA plasmacytomas may represent a distinct form of extramedullary plasmacytoma characterized by younger age at presentation, frequent lymph node involvement, and low risk of progression to plasma cell myeloma.
Institute. Clinical information and follow-up were obtained from submitted patient records or referring physicians. Relevant clinical information was summarized in Table 1 .
Histology and Immunohistochemistry
Morphology and immunohistochemical features were studied on formalin-fixed and paraffin-embedded (FFPE) tissue sections. Immunohistochemical stains were performed using an automated immunostainer (Ventana Medical Systems, Inc, Tucson, AZ) according to the company's protocols, with minor modifications. Antigen retrieval was performed using a Tender Cooker (Nordicware, Minneapolis, MN) with citrate buffer. Antibodies included CD20 (L26, 1:1000; Dako, Carpinteria, CA), CD79a (MB1, 1:400, Dako), Pax5 (24; 1:25; BD Transduction Laboratories), CD3 (F7.2.38, 1:50; Dako), CD19 (LE-CD19; 1:50; Dako), CD56 (1B6, 1:50; Novocastra), Cyclin D1 (SP4; 1:50; Neomarkers), CD138 (B-B4, 1:200, Dako), k (1:25,000; Dako), l (1:10,000; Dako), IgA (1:10,000; Dako), IgG (1:12,000; Dako), IgM (1:10,000; Dako), IgD (1:1000; Dako), Ki-67 (Ki-67, 1: 100, Dako), and Kaposi sarcoma-associated herpesvirus (human herpes virus type-8; HHV-8) (LN53 ORF73, 1:2000, Advance Biotechnologies Inc). Positive and negative controls were performed with all cases and showed appropriate staining patterns.
In-situ Hybridization Studies for Epstein-Barr virus
In-situ hybridization for Epstein-Barr virus-encoded RNA (EBER) was performed on formalin-fixed paraffin-embedded tissue sections using a fluorescein isothiocyanate-labeled oligonucleotide probe (Ventana Medical Systems, Tucson, AZ) on an automated stainer (Ventana-Benchmark, Tucson, AZ). Visualization was achieved using the in-situ hybridization iView system with alkaline-phosphatase and nitro blue tetrazolium/ 5-bromo-4-chloro-3-indolyl phosphate substrate, with fast red as contrast.
PCR Studies of IGH@ and IGK@ Gene Rearrangements
Genomic DNA was extracted from FFPE tissue sections using QIAamp DNA FFPE tissue kit (QIAGEN Inc, Valencia, CA) according to the manufacturer's instructions. For immunoglobulin heavy chain (IGH@) clonality assays, polymerase chain reaction (PCR) was performed on each sample using the framework 3 (VHa FRIII and JHa FRIII as reported by Segal et al 39 ) and framework 2 (FR2A as reported by Ramasamy et al 33 and JHa FRIII) consensus primers. A 50 mL PCR reaction mixture contained about 0.2 to 0.5 mg of DNA template in 1 Â buffer II (Applied Biosystem, Foster City, CA) with 2.0 mM magnesium chloride, 0.25 mM each deoxynucleotide triphosphate, 0.5 mM of each primer, and 1.25 units of AmpliTaq Gold DNA polymerase (Applied Biosystem). For k light chain (IGK@) clonality assays, PCR reaction using IGK@ Gene Clonality Assay for ABI Fluorescence Detection Kit (InVivoScribe Technologies) was performed according to the manufacturer's instructions. Briefly, 1 mg of DNA template was mixed in 1 Â IGK@ Tube A (or B) with 1.25 units of AmpliTaq Gold DNA polymerase (Applied Biosystem). The IGK@ primers were originally designed by BIOMED-2 concerted action BMH4-CT98-3936. 45 The DNA was amplified in a thermocycler (GeneAmp PCR System 9700, Applied Biosystems) for 7 minutes at 951C followed by either 35 cycles (FRIII and IGK@ PCR reactions) or 40 cycles (FRII reaction) of amplification (951C for 45 s; 601C for 45 s; and 721C for 90 s), and a final cycle of extension at 721C for 10 minutes. After amplification, the PCR products were analyzed using ABI Genetic Analyzer 3130 (Applied Biosystem). The valid PCR product size ranges were 70 to 140 bp for IGH@ FRIII; 220 to 300 bp for IGH@ FRII; 120 to 160 bp, 190 to 210 bp, 260 to 300 bp for IGK@ Tube A; and 210 to 250 bp, 270 to 300 bp, and 350 to 390 bp for IGK@ Tube B. For IGH@ FRIII and FRII PCR, clonal rearrangement was defined as a single peak or double peaks with height Z1000 fluorescent units and without a polyclonal background, or the height of the highest peak Z2.5 Â of average of 2 neighbor peaks for normal distribution of bands; or the height of highest peak Z1000 fluorescent units and Z3 Â of the third highest peak for skewed distribution of bands. For both IGK@ Tube A and B PCR, any peaks with height Z2000 fluorescent units were considered indicative of a clonal rearrangement, except a peak at 147 and 196 bp in IGK@ Tube A, which is a recurring nonspecific peak. 24, 45 The combined analysis of IGH@ and IGk can identify about 85% to 90% of all clonal B-cell proliferations.
RESULTS

Clinical Findings
The clinical data are summarized in Table 1 . There were 7 males and 5 females with an age range at initial presentation from 10 to 66 years (median, 32 y). Six of the patients were younger than 30 years of age including 4 males and 2 females. Nine patients had nodal disease without extranodal involvement, and 7 of them presented with multiple regional lymph nodes or generalized lymphadenopathy. One patient (number 8) had an incidental finding of plasmacytoma in dissected pelvic lymph nodes during surgery for endometrial carcinoma. Except for 2 patients (number 5 with mild splenomegaly, and number 9 with hepatosplenomegaly), all other patients showed no hepatosplenomegaly or constitutional symptoms such as fever, night sweats, or weight loss. Three patients presented with extranodal disease, 2 involving the nasopharynx and 1 with a soft tissue mass. Of 6 patients who had bone marrow biopsies, 5 had negative bone marrow examination and 1 showed increased polyclonal plasma cells (24%) in the bone marrow (number 4). Demographic features were compared with 16 extraosseous plasmacytomas expressing IgG. There were 10 males and 6 females; age range was (20) 20 to 88 years (median, 54 y). There were 9 nodal lesions and 7 extranodal, most of which involved nasopharyngeal or upper airway sites.
Immune system dysfunction was observed in 6 patients with nodal IgA-producing plasmacytomas, including 1 with human immunodeficiency virus (HIV) infection (number 6); 1 with T-cell deficiency (number 2); 2 with autoantibodies (numbers 3 and 5); 1 with Sjo¨gren syndrome, arthralgias, and hemolytic anemia (number 9); and 1 with decreased CD19-positive B-cells and arthritis (number 1). However, primary immune disorders such as Wiskott-Aldrich syndrome, common variable immunodeficiency, and autoimmune lymphoproliferative syndrome were not present in any patient. Immune system dysfunction was not observed in patients with extranodal plasmacytomas. Most patients had no previous history of hematologic malignancies with the exception of 2 patients, 1 with Burkitt lymphoma (number 2) and 1 with small lymphocytic lymphoma in a cervical lymph node and myelodysplastic syndrome (number 5). Both were treated and had no evidence of residual lymphoma at time of presentation with IgA plasmacytoma. Hypergammaglobulinemia was detected in 6 of 7 patients (86%) with nodal disease, and serum IgA was markedly elevated with absence of or only mild alterations of IgG or IgM levels. Serum protein electrophoresis and immunofixation studies showed an IgA M-protein in 6 of the 7 patients, including the case without hypergammaglobulinemia (number 3). Patient 1 had elevated IgA but no paraprotein. None of the patients with extranodal plasmacytomas had serum abnormalities (data available in 2 of 3).
Clinical follow-up was available in 7 patients, with a follow-up period after treatment ranging from 20 to 58 months (median, 34 mo). Case number 1 first presented with nodal disease at the age of 10 years, but was not treated until the age of 28 years and remains in complete remission (CR) 48 months later following Rituximab. Two other patients were treated with Rituximab (numbers 2 and 4), 1 of whom also received chemotherapy (number 4). Case number 2 was not responsive to monoclonal antibody therapy and had persistent but stable lymphadenopathy 31 months post diagnosis. Case number 4 remains in CR. One patient with extranodal laryngeal disease received radiation therapy and remains in CR. Three patients (numbers 8, 11, and 12) were not treated and remain asymptomatic and disease-free. Patient number 9 is still in an early phase of treatment with chemotherapy.
Morphologic and Immunohistochemical Findings
Morphologically, the lymph nodes showed an infiltrate of plasma cells that was either interfollicular (numbers 1, 2, 3, 5, and 8) or diffusely effacing nodal architecture (numbers 4, 6, 7, and 9). The interfollicular pattern was characterized by a largely preserved architecture with or without marked follicular hyperplasia, and patent or dilated sinuses ( Figs. 1, 2 ). The interfollicular/ paracortical areas showed sheets or aggregates of mature plasma cells; a focal paracortical nodular expansion of mature plasma cells was present in case 2. In lymph nodes with marked follicular hyperplasia (numbers 1 and 3), the lymphoid follicles were hyperplastic and the mantle zones were of normal thickness with polarization. Case 1 also showed some small atrophic lymphoid follicles, slightly increased vascularity between the lymphoid follicles and focally increased eosinophils. However, the mantle zones were not markedly thickened in the atrophic follicles and the interfollicular blood vessels were not hyalinized. The plasma cells were mature Marschalko type with little pleomorphism in 2 cases (numbers 1 and 5). The plasma cells in case 3 were largely immature with less condensed chromatin and higher N:C ratio (Fig. 2D ). Increased numbers of atypical forms with enlarged nuclei and binucleation or multinucleation were present in 2 cases (numbers 2 and 8) (Figs. 2B, F) , and intranuclear pseudoinclusions (Dutcher bodies) and Russell bodies were readily identified. Mitotic figures were rarely found. The interfollicular plasma cells in all cases expressed IgA with immunoglobulin light chain restriction. In cases with marked follicular hyperplasia (numbers 1 and 3), small numbers of IgG-positive polyclonal plasma cells were identified in the germinal centers (Figs. 1D, E, G).
Four cases (numbers 4, 6, 7, and 9) showed effacement of nodal architecture by a diffuse infiltrate of mature plasma cells. Only few scattered lymphoid follicles composed of small lymphocytes were observed (number 9), sometimes only evident by immunohistochemical stains (Fig. 3C ). The plasma cells were mature with little atypia, rare intranuclear inclusions, and rare mitotic figures.
Three cases presented with extranodal disease (numbers 10 to 12). One case with laryngeal involvement and 1 presenting as a soft tissue mass were composed of uniform sheets of mature plasma cells. Case 11, presenting in the nasopharynx, exhibited interfollicular infiltration by mature plasma cells with intervening reactive follicles.
Equal numbers of cases expressed k or l light chain (6k:6l). CD20 was negative in 11 of 12 cases, with focal expression seen in number 3. The plasma cells were positive for CD138 and negative for CD56 and Cyclin D1 in all 12 cases. They were positive for CD19 in 6 of 9 cases tested ( Table 2 ). In case 4, EBER showed small numbers of Epstein-Barr virus (EBV)-positive cells in loose clusters that corresponded to CD20 positive B-cells. EBV RNA was not detected by EBER in the plasma cells or lymphocytes in other cases. Immunostains for HHV-8 were negative in all cases.
Molecular Genetic Findings
Cytogenetic studies were performed in 3 patients (numbers 2, 3, and 5), and PCR analysis for IGH@ and IGK gene rearrangement was successful in 11 patients. One patient had a normal karyotype, whereas 2 had abnormal karyotypes, including t(14;15) and trisomy 1 (number 2), and dup(1)(q21q31) (number 3). Seven of 11 cases with successful PCR amplification (64%) showed clonal IGH@ and/or IGK@ rearrangements, 60% (3 of 5) in cases with an interfollicular pattern of infiltration, and 66% (4 of 6) in cases with a diffuse plasma cell infiltrate. Four cases, 2 interfollicular (numbers 1 and 2) and 2 diffuse (numbers 6 and 9), lacked definite evidence of a clonal population by IGH@ and IGK@ gene rearrangement, despite apparent light chain restriction by immunohistochemistry. Case 9 showed a peak highly suspicious for but not diagnostic of clonal IGH@ gene rearrangement in IGH@ FRII PCR reaction. These 4 patients had multiple sites of lymphadenopathy, and 3 were below the age of 30 years. In patient 2, there was evidence of clonality by cytogenetic studies, suggesting that the normal PCR result for immunoglobulin gene rearrangement was a false-negative.
DISCUSSION
In this study, we analyzed the clinicopathologic features of 12 cases of EMP with exclusive expression of IgA (referred to as IgA plasmacytoma in the discussion). Our study shows that IgA plasmacytomas exhibit several distinctive features: (1) a high percentage of patients below 30 years of age (6 of 12; 50%); (2) more common presentation in nodal, rather than extranodal sites (9 of 12; 75%); (3) frequent involvement of multiple lymph node sites, rather than solitary lesions; and (4) absence of progression to plasma cell myeloma in all patients herein reported.
Another notable feature was that 67% (6 of 9) patients with nodal IgA plasmacytomas (numbers 1, 2, 3, 5, 6, and 9) had evidence of some immune system dysfunction such as arthritis, Sjo¨gren syndrome, autoantibodies with autoimmune phenomena, and T-cell deficiency including HIV-infection. Autoimmune diseases, such as Hashimoto thyroiditis, Sjo¨gren syndrome, multiple sclerosis, and the acquired immunodeficiency syndrome have been associated with expansion of monoclonal B-cells, 10, 18, 22, 28, 36 and even IgA-positive plasma cells. 48 Autoimmune diseases are at least partially mediated by abnormal T cell and/or T-cell-dependent B-cell responses against self-antigens, and it is well established that transforming growth factor-b produced by a subset of helper T-cells, known as T H 3 cells, is essential for IgA production. 6, 11, 30 Therefore, there is a potential link between T-cell dysfunction, autoimmunity, and IgA-producing plasma cells. Given the benign clinical course of most IgA plasmacytomas, it is tempting to speculate that at least some of the cases represent exaggerated monotypic/monoclonal plasma cell proliferations related to dysregulated immune function, rather than an autonomous neoplastic proliferation. In contrast, plasma cell myeloma expressing IgA is a truly neoplastic process with some data indicating a more aggressive clinical course compared with that of plasma cell myeloma expressing IgG. 47 A notable feature of IgA plasmacytoma was the low median age at presentation, 32 years, in contrast to a median age of 54 years for our cases of IgG plasmacytoma. Similar to our data Menke et al 27 identified a median age of 60 years for their cases of nodal plasmacytoma, most of which expressed IgG. In contrast, 6 of the patients with IgA plasmacytomas, 5 of whom presented with nodal lesions, were less than 30 years of age. Notably, plasma cell myeloma is a disease of middleaged to elderly patients, and rarely occurs in adults below 30 years of age. 21, 47 Moreover, IgA-producing myeloma is not usually associated with a younger age at presentation, with only 4.3% presenting below the age of 40 years. 47 However, there are multiple reports of IgA myeloma occurring in younger patients with autoimmune disease. 4, 7, 16, 31, 43 Some of these cases seem to overlap with IgA nodal plasmacytomas in having a low risk of lytic bone disease but generalized lymphadenopathy. 7 Earlier studies have identified monoclonal gammopathy in approximately 20% of EMPs. 17, 40, 41 In our study, monoclonal gammopathy was present in the majority of patients with nodal disease tested, but none It is difficult to draw conclusions regarding the clinical outcome of IgA EMPs, given the heterogeneous therapies used. However, all patients with available follow-up are alive, either with (1) or without (6) detectable disease. One recent case (number 9) has only recently initiated therapy. None of the patients in our study showed progression to plasma cell myeloma.
PCR analysis showed clonal IGH@ and/or IGK@ gene rearrangements in 64% (7 of 11) of cases with amplifiable DNA, supporting the clonal nature of plasma cell proliferation. The clonal nature of the plasma cells in case 4 was indirectly proven by the presence of monoclonal IgA M-spike detected by serum protein electrophoresis and immunofixation, but DNA was degraded and could not be amplified. One of the remaining PCRnegative cases had a clonal cytogenetic abnormality t(14;15) and trisomy 1 (number 2). The abnormal cytogenetic findings, t(14;15) and dup(1)(q21q31) in patients 2 and 3, have not been described in plasmacytoma or plasma cell myeloma, and their clinical significance is unclear.
The diagnosis of IgA plasmacytoma was based on total or subtotal effacement by monoclonal plasma cells expressing IgA in lymph nodes or other extranodal site without evidence of bone marrow involvement. None of the patients had clinical or radiographic evidence of plasma cell myeloma. Partial vertebral compression fractures, rib fractures, and distal tibia bone infarcts in patient 5 were felt clinically to be related to osteoporosis, and bone marrow examination was negative. Only 1 patient (number 4) had significant plasmacytosis in the marrow. However, immunostains showed that the bone marrow plasma cells were polyclonal. Furthermore, the immunophenotypic features argued against a diagnosis of myeloma, as the plasma cells were generally positive for CD19 and negative for both CD56 and cyclin D1.
The differential diagnosis of nodal plasmacytoma includes marginal zone lymphoma (MZL) and lymphoplasmacytic lymphomas (LPL), both of which may have evidence of plasmacytic differentiation. 8, 29, 35, 38, 44 The distinction between plasmacytoma and MZL and LPL with extensive plasmacytoid differentiation is sometime problematic. Arguing against MZL and LPL was the absence of B-lymphocytes with plasmacytoid or monocytoid features, and absence of marginal zone expansion. 5 The atypical plasma cells lacked CD20, and in cases in which follicular hyperplasia was present, the plasma cells within the reactive follicles were negative for IgA and polytypic for k and l. It has been noted that EMP in the head and neck region may progress to involve adjacent lymph nodes. 1, 12, 19 However, the patients characterized as nodal plasmacytoma had no evidence of an extranodal mass lesion.
Histologically, IgA plasmacytomas had either an interfollicular or diffuse pattern of infiltration. No differences were observed according to the pattern of infiltration, either in clinical manifestations or clonality by genetic studies, although the number of cases is small. The plasma cells were mostly of mature Marschalko-type, corresponding to histologic grade 1 devised by Bartl et al 2 for plasma cell myeloma, with only 1 case showing more immature plasma cells (number 3). In cases with an interfollicular plasma cell infiltrate, the combination of interfollicular plasmacytosis, follicular hyperplasia, and increased paracortical vascularity may raise the possibility of the plasma cell variant of Castleman disease (PC-CD). Morphologically, PC-CD exhibits preserved follicles with either regressive features, or hyperplastic germinal centers in some cases, and sheets of interfollicular plasma cells. 15, 32 The plasma cells in some PC-CD may be monoclonal, usually with l light chain restriction. 15, 26, 32 The majority expresses IgG and a small subset also expresses IgA. 15, 26, 32 Only 1 case in our series (case 1) had some follicles with regressive features, but there was no expansion of the mantle zones. In addition, the plasma cells were k light chain restricted.
The patients lacked the symptomatology (fever, night sweats, and weight loss) or hepatosplenomegaly (with the exception of case 9) of multicentric Castleman disease. In addition, all cases were negative for HHV-8, including the patient with HIV infection (number 6). Rare case reports of synchronous or metachronous plasmacytoma associated with multicentric Castleman disease have been described. 9, 14, 37 However, none of our patients had a history suggestive of such a preexistent condition. Similarly, EBER was negative in all cases, with the exception of 1 case (number 4) in which a small number of CD20-positive B-cells were positive; the plasma cells were negative for EBV.
In conclusion, extramedullary IgA plasmacytomas are associated with several distinctive features, including young age at presentation, low risk for progression to plasma cell myeloma, and association with autoimmune disease or immune dysfunction. Detailed clinical, laboratory, and radiographic studies are necessary to rule out IgA producing myeloma for proper clinical management, especially in patients above 30 years of age.
